A Study of Foretinib in Patients With Recurrent/Metastatic Breast Cancer
Status:
Completed
Trial end date:
2015-02-13
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out what effects this new drug foretinib has on this
type of breast cancer, called "triple negative" breast cancer because the cancer tissue is
estrogen, progesterone and HER2 receptor negative.